AstraZeneca PLC (AZN)vsSTAAR Surgical Company (STAA)
AZN
AstraZeneca PLC
$185.95
+2.60%
HEALTHCARE · Cap: $282.69B
STAA
STAAR Surgical Company
$28.83
+0.44%
HEALTHCARE · Cap: $1.41B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 20714% more annual revenue ($60.44B vs $290.38M). AZN leads profitability with a 17.2% profit margin vs -7.2%. STAA appears more attractively valued with a PEG of 0.76. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
STAA
Hold47
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.1%
Fair Value
$194.57
Current Price
$185.95
$8.62 discount
Margin of Safety
+44.9%
Fair Value
$31.32
Current Price
$28.83
$2.49 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Revenue surging 119.6% year-over-year
Conservative balance sheet, low leverage
Growing faster than its price suggests
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Grey zone — moderate risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -6.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : STAA
The strongest argument for STAA centers on Revenue Growth, Debt/Equity, PEG Ratio. Revenue growth of 119.6% demonstrates continued momentum. PEG of 0.76 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : STAA
The primary concerns for STAA are Altman Z-Score, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while STAA is a hypergrowth play — different risk/reward profiles.
STAA carries more volatility with a beta of 1.23 — expect wider price swings.
STAA is growing revenue faster at 119.6% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 47/100), backed by strong 17.2% margins and 12.5% revenue growth. STAA offers better value entry with a 44.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
STAAR Surgical Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
STAAR Surgical Company designs, develops, manufactures, markets and sells implantable eye lenses and supplemental delivery systems for placing the lenses in the eye. The company is headquartered in Lake Forest, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?